XJPX
6568
Market cap60mUSD
Oct 09, Last price
1,239.00JPY
1D
0.00%
1Q
-6.84%
IPO
-63.45%
Name
KNC Laboratories Co Ltd
Chart & performance
P/E
12.52
P/S
1.05
EPS
98.98
Div yield, %
2.66%
Shrs. gr., 5y
-0.04%
Rev. gr., 5y
8.57%
Revenues
9.09b
+11.18%
Net income
766m
+3.92%
CFO
2.26b
+52.15%
Dividend
Mar 30, 202717 JPY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
KNC Laboratories Co., Ltd. engages in research, development, and production solutions for organic chemicals. Its operations are carried out through the following business divisions: Functional Materials Business, Pharmaceutical Business, and Bio Business. The Functional Materials Business division provides display materials, chemicals for semiconductor manufacturing, carbon nanotube dispersions, etc. The Pharmaceutical Business division provides compounds for pharmaceutical research and development. The Bio Business Division provides auxiliary agents for antibody drug manufacturing. The company was founded on January 22, 1985 and is headquartered in Kobe, Japan.
Key people
Masahiro Neya
Managing Director, Director of Reliability Assurance Promotion · since 2024
Koji Matsuo
Executive Officer, Director of Sales Management · since 2022
Atsushi Kaetsu
Executive Officer, Director of Pharmaceutical Business
Junichi Miyahara
Executive Officer, Director of Biotechnology Business, Director of Life Science
Kimihiro Kamasaka
Director of Functional Materials Business, Director · since 2024
Hidemi Yoshida
Director of Functional Materials Business, Director · since 2022
Ryuichi Inoue
Director · since 2024
Takuya Mooka
President, Chief Director of Administration, Representative Director · since 2025
Osamu Maruyama
Independent Director · since 2022
Mitsukuni Mori
Independent Director · since 2017
Headquarters & legal address
港島南町七丁目1番地の19
兵庫県 神戸市中央区 650-0047
JP
兵庫県 神戸市中央区 650-0047
JP
Address
7-1-19 Minatojimaminamimachi
Chuo-ku, Kobe Hyogo 650-0047
JP
Chuo-ku, Kobe Hyogo 650-0047
JP
Other language
KNC Laboratories Co., Ltd.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||